Skip to main content
Cantargia logo

Cantargia — Investor Relations & Filings

Ticker · CANTA ISIN · SE0023312970 LEI · 549300GKWRT7RXI4VS85 ST Manufacturing
Open in API
Filings indexed 511 across all filing types
Latest filing 2024-04-18 AGM Information
Country SE Sweden
Listing ST CANTA

About Cantargia

https://cantargia.com/en/

Cantargia is a biotechnology company that develops antibody-based therapies targeting the interleukin-1 receptor accessory protein (IL1RAP). This protein is involved in signaling pathways that can drive cancer and inflammatory diseases. The company's lead asset, nadunolimab (CAN04), is a clinical-stage antibody under investigation for the treatment of various forms of cancer, including pancreatic cancer. Cantargia also developed the CAN10 program, an antibody targeting IL1RAP for autoimmune and inflammatory conditions, which was acquired by Otsuka Pharmaceutical.

Recent filings

Filing Released Lang Actions
Kallelse till årsstämma i Cantargia AB (publ)
AGM Information Classification · 100% confidence The document is titled "Kallelse till årsstämma i Cantargia AB (publ)" which translates to 'Notice of Annual General Meeting in Cantargia AB (publ)'. It details the date, time, location, procedures for participation (in person or by postal vote), and the proposed agenda for the meeting. The agenda items cover standard AGM topics like electing the chairman, approving the annual report, deciding on profit distribution, setting director/auditor fees, and voting on remuneration guidelines and incentive programs. This content is characteristic of a formal notice calling shareholders to an Annual General Meeting (AGM). The closest specific category is AGM Information (AGM-R), as it is the notice/material for the AGM itself, rather than a Proxy Statement (PSI) which typically solicits votes based on detailed proposals, or a DEF 14A which focuses solely on remuneration.
2024-04-18 Swedish
Cantargia presents new human data further supporting CAN10 in the treatment of systemic sclerosis
Regulatory Filings Classification · 95% confidence The document is a press release announcing new scientific data regarding the CAN10 antibody presented at a medical congress (Systemic Sclerosis World Congress). It details research findings, quotes the CEO, and mentions that the information is being released pursuant to the EU Market Abuse Regulation. Crucially, the final section includes an 'Attachments' link to a PDF document, and the text itself is an announcement about the data presentation, not the full financial report (10-K, IR) or a transcript (CT). The closing statement, 'This information is information that Cantargia is obliged to make public pursuant to the EU Market Abuse Regulation,' strongly suggests a general regulatory disclosure. Since it is an announcement about research/data presentation and not a standard financial report, dividend notice, or management change, the most appropriate general category for a non-standard regulatory disclosure that doesn't fit elsewhere is Regulatory Filings (RNS). It is not an Earnings Release (ER) as it focuses on clinical data, not financial performance highlights.
2024-03-14 English
Cantargia presenterar nya humana data som ger ytterligare stöd för CAN10 vid behandling av systemisk skleros
Regulatory Filings Classification · 96% confidence The document is a press release from Cantargia (a biotech company) announcing new clinical data supporting its drug candidate CAN10 for treating systemic sclerosis. It details scientific findings, quotes the CEO, mentions upcoming presentation at a congress, and concludes with a statement about being information the company is required to disclose under EU Market Abuse Regulation, followed by links to a PDF attachment. The key indicator is the structure: a news announcement about scientific progress and data presentation, rather than a formal regulatory filing like a 10-K, an earnings release (ER), or a detailed management discussion (MDA). Since it is an announcement of results/data, and not a formal financial report, it fits best as a general Regulatory Filing (RNS) or potentially an Investor Presentation (IP) if it were the presentation itself. However, given the format is a press release announcing data that will be presented elsewhere (and linking to a PDF), RNS (Regulatory Filings/General Announcement) is the most appropriate general category for non-standard, material company news that isn't explicitly covered by other codes like ER or DIV. The document length (6456 chars) is substantial enough that it is not just a brief RPA, but a full announcement.
2024-03-14 Swedish
Interim / Quarterly Report 2023
Interim / Quarterly Report Classification · 100% confidence The document is a 'Bokslutskommuniké' (Year-End Report) for the period January–December 2023. It contains comprehensive financial data, including income statements, balance sheet highlights, management commentary, and detailed project updates. It is a full financial report for a period shorter than a full fiscal year (or a year-end summary), which fits the definition of an Interim/Quarterly Report (IR) in the provided taxonomy. FY 2023
2024-02-22 Swedish
Interim / Quarterly Report 2023
Interim / Quarterly Report Classification · 100% confidence The document is titled 'YEAR-END REPORT' and 'FULL YEAR REPORT' for the period January–December 2023. It contains comprehensive financial data, including net sales, operating loss, loss after tax, loss per share, and equity/assets ratios for both the full year and the fourth quarter. It also includes a 'Chief Executive's Review', detailed project portfolio updates, and clinical study results. This meets the criteria for an Interim/Quarterly Report (IR) as it provides substantive financial statements and analysis for a period shorter than a full fiscal year (or in this case, a year-end report that functions as a comprehensive periodic financial update). FY 2023
2024-02-22 English
Cantargia reports US regulatory approval to start pancreatic cancer phase IIb trial with nadunolimab
Regulatory Filings Classification · 95% confidence The document is a press release announcing that Cantargia has received US regulatory approval (FDA) to start a Phase IIb clinical trial for its drug nadunolimab in pancreatic cancer. It details the trial design, expected timeline, and provides background on the company and the drug. This type of announcement, which reports on a specific operational or regulatory event (clinical trial approval) rather than comprehensive financial results (10-K, IR, ER) or management changes (MANG), fits best under the general category of Regulatory Filings (RNS) or potentially a specialized announcement if one were available. Since it is a specific, non-financial regulatory update concerning clinical trials, and it is not a standard financial report, RNS (Regulatory Filings) is the most appropriate general classification for significant, non-standard corporate news that doesn't fit the other specific codes (like DIV, CAP, MANG, etc.). The document length (5014 chars) is substantial enough that it is the report itself, not just an announcement of a report (which would lean towards RPA/RNS based on the 'Menu vs Meal' rule, but here the content *is* the news). Given the content is a regulatory/operational update, RNS is the best fit among the available options.
2024-02-20 English

Browse filings by year

9 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.